Strategies for Mitigating AI Bias in Healthcare
- Jun 26
- 6 min read
Artificial intelligence pilots are happening across healthcare, pharma, digital health, and life sciences.
Organizations are testing AI tools for documentation, operations, patient engagement, clinical decision support, trial recruitment, data review, revenue cycle, and workflow automation. Many of these pilots are promising.
But too often, they do not scale.
The issue is rarely that the AI tool was not interesting. The issue is that the organization did not have the strategy, governance, workflow design, measurement plan, and accountability needed to move from pilot to implementation.
In healthcare, AI pilots fail when they are treated as technology experiments instead of operational change initiatives.
Why AI Pilots Struggle in Healthcare
AI pilots often begin with enthusiasm. A team identifies a tool, launches a small test, and looks for early signs of value.
But healthcare environments are complex. A tool that works in a limited setting may not translate across departments, sites, patient populations, or workflows.
Common reasons AI pilots fail include:
unclear problem definition
weak alignment with clinical or business priorities
limited workflow integration
insufficient validation
poor user adoption
unclear ownership
lack of governance
privacy or compliance concerns
inadequate vendor accountability
no post-deployment monitoring plan
unclear success metrics
AI pilots do not fail only because of technology. They fail because the implementation strategy was not designed from the start.
Start With the Problem, Not the Tool
A strong AI pilot begins with a clearly defined problem.
Before selecting or testing an AI tool, leaders should ask:
What problem are we trying to solve?
Why does this problem matter now?
Who is affected by the problem?
What workflow will change if the AI tool works?
What outcome are we trying to improve?
How will we measure success?
What risks could this create?
Too many pilots start with the question, “What can this AI tool do?”
A better question is, “What problem is important enough to justify AI implementation?”
This distinction matters. AI should be connected to measurable priorities such as patient safety, access, quality, efficiency, staff burden, trial performance, or operational reliability.
Define Success Before Launch
AI pilots often fail because success is not clearly defined.
A vendor may define success by technical performance. A clinical team may define success by usability. Executives may define success by return on investment.
Compliance teams may define success by risk reduction. Patients may define success by access, clarity, or experience.
All of these perspectives matter.
Before launching a pilot, organizations should define success across multiple dimensions:
clinical or operational impact
user adoption
workflow fit
safety
privacy and security
bias and equity
efficiency
cost or resource impact
patient or participant experience
scalability
governance readiness
A pilot should not only answer whether an AI tool works. It should answer whether the tool is worth scaling.
Build Governance Into the Pilot
Governance should not begin after a pilot shows promise.
It should be built into the pilot design.
A practical AI pilot governance process should include:
intended use review
risk tiering
vendor evaluation
privacy and security review
bias and fairness assessment
validation expectations
human oversight requirements
workflow impact review
monitoring plan
escalation process
documentation standards
This does not mean every pilot needs a burdensome approval process. It means oversight should match the level of risk.
A low-risk internal productivity pilot may need basic guardrails. A pilot that affects clinical decisions, patient communication, trial eligibility, safety monitoring, or resource allocation requires much stronger review.
Involve the People Who Will Use the Tool
AI implementation often fails when pilots are designed without enough input from the people who will use the tool.
Clinicians, staff, trial teams, operations leaders, compliance teams, and end users need to be involved early. They understand the workflow, the pain points, the failure modes, and the practical barriers to adoption.
Before launching a pilot, organizations should ask:
Who will use the AI output?
When will they see it?
What action are they expected to take?
Does the output fit the workflow?
Will the tool reduce burden or add work?
What training is needed?
How will users provide feedback?
What concerns do frontline teams have?
A technically strong AI tool can still fail if it does not fit how work actually happens.
Validate for the Intended Setting
AI performance is context-dependent.
A model or AI tool may perform well in one setting but not in another. Differences in patient populations, data quality, documentation practices, staffing, EHR configuration, clinical workflows, or site resources can affect performance.
Validation should consider:
intended use
patient or participant population
care setting or trial context
data sources
workflow integration
subgroup performance
human oversight
known limitations
failure modes
operational constraints
For healthcare and life sciences organizations, validation should not be viewed as a technical checkbox. It is a safety, trust, and implementation requirement.
Plan for Equity and Bias From the Start
AI pilots should include early assessment of bias and equity risk.
A pilot may appear successful overall while creating different outcomes across patient groups, sites, languages, geographies, or access levels. This is especially important when AI influences care navigation, risk prediction, trial recruitment, outreach, diagnosis, treatment recommendations, or resource allocation.
Organizations should ask:
Who may benefit from this tool?
Who may be excluded?
Does the tool perform differently across groups?
Are outputs actionable for all populations?
Could the tool worsen disparities?
How will subgroup performance be monitored?
What mitigation plan is in place if equity concerns emerge?
Equity should not be evaluated only after scaling. It should be part of pilot design.
Address Vendor Accountability Early
Many AI pilots involve vendor-developed tools. This makes vendor accountability essential.
Organizations should clarify:
what the tool is intended to do
what evidence supports its use
what data were used for development and validation
what limitations are known
how bias and fairness were evaluated
what data the vendor can access
whether data are used to train or improve vendor models
how model updates are handled
what monitoring data will be provided
what happens if performance declines
Vendor claims should not replace organizational due diligence.
The organization using the AI tool remains responsible for how it is deployed in its environment.
Create a Path From Pilot to Scale
A pilot should be designed with the end in mind.
If the tool works, what happens next?
Before launch, leaders should define:
what evidence is needed to expand
who approves scaling
what additional validation is required
what workflows need to change
what training is needed
what monitoring will continue
what resources are required
what risks need mitigation
what contract terms need review
what success metrics must be sustained
Without a scale pathway, even promising pilots can stall.
Know When Not to Scale
Not every AI pilot should become an enterprise deployment.
Sometimes the right decision is to stop.
Organizations should be willing to pause, redesign, or end a pilot if:
the tool does not solve a meaningful problem
performance is inadequate
workflow burden is too high
users do not trust the output
privacy or security concerns remain unresolved
bias or equity concerns emerge
vendor documentation is insufficient
the tool cannot be monitored
the return on investment is unclear
the implementation risk outweighs the benefit
Responsible AI includes knowing when not to scale.
What Leaders Should Do Now
Healthcare, pharma, digital health, and life sciences leaders should ask:
Are our AI pilots tied to clear organizational priorities?
Have we defined success before launch?
Do we have governance built into pilot design?
Have we validated the tool for the intended setting?
Are frontline users involved early?
Have we assessed bias, fairness, and equity risk?
Are vendor responsibilities clearly defined?
Do we have a monitoring plan?
Do we know what evidence is needed to scale?
Are we willing to stop pilots that do not meet expectations?
If the answers are unclear, AI pilots may be moving faster than governance.
Responsible Scale Requires More Than a Successful Pilot
AI pilots are useful, but they are not the destination.
The goal is responsible implementation.
Organizations that lead in healthcare AI will not be those with the most pilots. They will be the organizations that can identify high-value use cases, validate tools responsibly, integrate them into workflows, monitor performance, and scale only when the evidence supports it.
AI pilots fail when they are disconnected from strategy, governance, and real-world implementation.
They succeed when they are designed as the first step in a responsible AI operating model.
Need Support Moving From AI Pilot to Responsible Scale?
CROSS Global Research & Strategy advises healthcare, pharma, digital health, and life sciences organizations on responsible AI strategy, governance, validation, and implementation.
We help teams identify high-value AI use cases, evaluate vendor risk, design pilot governance, define success metrics, assess readiness, and build scale pathways that support patient safety, equity, trust, and regulatory readiness.
To discuss how your organization can move from AI experimentation to responsible implementation, contact CROSS Global Research & Strategy.
Suggested References
National Institute of Standards and Technology. Artificial Intelligence Risk Management Framework (AI RMF 1.0). National Institute of Standards and Technology; 2023.
Coalition for Health AI. Blueprint for Trustworthy AI Implementation Guidance and Assurance for Healthcare. Coalition for Health AI. 2026
World Health Organization. Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. World Health Organization; 2021.
US Food and Drug Administration. Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. Draft Guidance for Industry and Food and Drug Administration Staff. US Food and Drug Administration; 2025.
URAC. Health Care AI: Accountability in Practice. URAC. 2026
Comments